Avid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Parenteral Manufacturing
28 juil. 2020 08h05 HE
|
Avid Bioservices, Inc; Argonaut Manufacturing Services
TUSTIN, Calif. and CARLSBAD, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing...
Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites
13 juil. 2020 13h42 HE
|
BioSig Technologies, Inc.
Westport, CT, July 13, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company") and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced the...
Cambridge Security Seals Launches A-MVB™ Line of Tamper-Evident Seals Equipped to Combat the Spread of Viruses and Diseases
08 juil. 2020 09h20 HE
|
Cambridge Security Seals
Pomona, New York, July 08, 2020 (GLOBE NEWSWIRE) -- Cambridge Security Seals (CSS), a global leader in tamper-evident seals and security solutions, today unveiled its A-MVB™ line of antimicrobial,...
C-Bond Systems Announces Exclusive Nationwide Distribution Agreement for EPA Registered Disinfectant MB-10 Tablets Approved for Use Against Human Coronavirus SARS-CoV-2
01 juin 2020 08h31 HE
|
C-Bond Systems
HOUSTON, June 01, 2020 (GLOBE NEWSWIRE) -- C-Bond Systems, Inc. (“C-Bond”) (OTC: CBNT), a nanotechnology solutions company, announced today that it has entered into an exclusive, nationwide...
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
28 mai 2020 08h00 HE
|
ARCA biopharma, Inc.
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study
28 mai 2020 03h00 HE
|
Atriva Therapeutics GmbH
ATR-002 mode of action inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in preclinical studiesAtriva’s lead product candidate is the only host-targeted antiviral...
C-Bond Systems’ Manufacturing Facility Receives EPA Registration
30 avr. 2020 08h31 HE
|
C-Bond Systems
HOUSTON, April 30, 2020 (GLOBE NEWSWIRE) -- C-Bond Systems, Inc. (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, today announced its manufacturing facility has received...
C-Bond Systems Partners with THOMS Aviation, THOMS Automotive, and EXEGi Trading Company in Joint Marketing and Distribution Agreements to Expand its Nano Products Portfolio
30 mars 2020 08h31 HE
|
C-Bond Systems
THOMS Aviation and Automotive Products include Antibacterial and Antiviral Protection for Covid-19 and Other Pathogens THOMS’ Current Customers Include Transavia, KLM Cityhopper and EasyJet HOUSTON,...
Business Capital Delivers $5.5 Million Financing for Wedderspoon
14 janv. 2020 07h00 HE
|
Business Capital
SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Business Capital structured and delivered a $5.5MM working capital facility for Wedderspoon, the largest seller of Manuka honey and its portfolio of...
Novan Further Expands its Proprietary Nitric Oxide Platform
18 oct. 2019 08h30 HE
|
Novan, Inc.
A new product candidate, SB207, to target anti-viral opportunitiesPre-IND meeting anticipated in December 2019Development of SB207 to be focused on indications with unmet patient need, such as...